Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Interleukin 17 signaling pathway is mediated by IL-17 family cytokines (primarily IL-17A and IL-17F) binding to multimeric cytokine receptor complexes composed of different IL-17 receptor subunits, most frequently IL-17RA paired with IL-17RC. Upon activation, these receptors initiate intracellular signaling via adaptors such as Act1, activating downstream mediators including NF-κB, MAPK, and others, resulting in the induction of inflammatory genes, chemokine production, antimicrobial peptide expression, and tissue remodeling. Dysregulation of IL-17 signaling is implicated in autoimmune and inflammatory diseases, as well as certain cancers and infections, making these receptors important drug targets.
Monoclonal antibodies blocking IL-17A ligand-receptor interaction Antibodies inhibiting IL-17RA receptor function
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 17 receptor (IL-17R) (IL-17R).